Insider transactions

Steven Kelly

CIK 1339478 · President and CEO · last filed 2026-07-21

Steven Kelly is a President and CEO who has filed 17 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for ARTL, was dated Jul 21, 2026.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$0
Companies
3
Total Filings
17
Lifetime Open-Market Net
$0

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

ARTLW price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O INNOVIVE PHARMACEUTICALS, INC.
555 MADISON AVENUE, 25TH FLOOR
NEW YORK, NY 10022
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ARTL Director — $3.26 — $0 3 2026-07-21
Carisma Therapeutics Inc. (CARM) Delisted President and CEO — $0.00 — $0 4 2025-01-30
ARTELO BIOSCIENCES, INC. (ARTLW) Delisted Director — $0.01 — $0 7 2024-03-01

Recent Filings

17 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-21 ARTL Grant (A) — $0 EDGAR
2026-02-02 ARTL Grant (A) — $0 EDGAR
2025-01-30 Carisma Therapeutics Inc. (CARM) Delisted Grant (A) — $0 EDGAR
2024-12-23 ARTL Grant (A) — $0 EDGAR
2024-06-18 Carisma Therapeutics Inc. (CARM) Delisted Grant (A) — $0 EDGAR
2024-03-01 ARTELO BIOSCIENCES, INC. (ARTLW) Delisted Mixed — $0 EDGAR
2024-02-02 Carisma Therapeutics Inc. (CARM) Delisted Grant (A) — $0 EDGAR
2023-08-08 ARTELO BIOSCIENCES, INC. (ARTLW) Delisted Grant (A) — $0 EDGAR
2023-07-03 ARTELO BIOSCIENCES, INC. (ARTLW) Delisted Grant (A) — $0 EDGAR
2023-06-08 Carisma Therapeutics Inc. (CARM) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 17
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.